Summary
Parkinson disease (PD) is the second most common neurodegenerative disorder. Recent studies have consistently demonstrated that in some families, disease is attributable to a mutation in a single gene. To date, genetic analyses have detected linkage to six chromosomal regions and have identified three causative genes: PARK1 (alpha-synuclein), PARK2 (parkin), and PARK7 (DJ-1). In addition, mutations in several other genes have been implicated in familial PD. Identification of the mutations in these genes has led to the recognition that the ubiquitin—proteasome system is an important pathway that may be disrupted in PD. Studies are ongoing to identify additional genes that may contribute to PD susceptibility, particularly in late-onset families without a clear pattern of disease inheritance. With the identification of mutations in particular genes and the likely role of additional genes that are important in PD risk-susceptibility, appropriate protocols must be developed so that accurate and informative genetic counseling can be offered to families in which one or more members has PD. Further diagnostic testing should be delayed until more is learned about the frequency, penetrance, and risk assessment of certain gene mutations. Important lessons can be learned from the implementation of counseling protocols for other neurodegenerative disorders, such as Huntington disease and Alzheimer disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Gowers WR. A Manual of the Diseases of the Nervous System. 2nd ed. Philadelphia: Blakiston, 1902.
Leroux P-D. Contribution a l’etude des causes de laparalysie agitante. In: These de Paris, 1880.
Scarpalezos S. Sur la notion d’heredite similaire dans la maladie de Parkinson.Rev Neurol 80: 184, 1948.
Tanner CM, Ottmann R, Goldman SM, Ellenberg J, Chan P, Mayeux R et al. Parkinson’s disease in twins: an etiologic study.JAMA 281: 341–346, 1999.
Martin WE, Young WI, Anderson VE. Parkinson’s disease: a genetic study.Brain 96: 495–506, 1973.
Barbeau A, Roy M, Boyer L. Genetic studies in Parkinson’s disease.Adv Neurol 40: 333–339, 1984.
Alonso ME, Otero E, D’Regules R, Figueroa HH. Parkinson’s disease: a genetic study.Can J Neurol Sci 13: 248–251, 1986.
Duvoisin RC, Johnson WG. Hereditary Lewy-body parkinsonism and evidence for a genetic etiology of Parkinson’s disease.Brain Pathol 2: 309–320, 1992.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families.Hum Mol Genet 12: 2599–2608, 2003.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease.Science 276: 2045–2047, 1997.
Bostantjopoulou S, Katsarou Z, Papadimitriou A, Veletza V, Hatzigeorgiou G, Lees A. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation.Mov Disord 16: 1007–1013, 2001.
Gasser T. Genetics of Parkinson’s disease.J Neurol 248: 833–840, 2001.
Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease.Nat Genet 18: 106–108, 1998.
Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J. Alpha-synuclein locus triplication causes Parkinson disease.Science 302: 841, 2003.
Pastor P, Munoz E, Ezquerra M, Obach V, Marti MJ, Valldeoriola F et al. Analysis of the coding and the 5′ flanking regions of the alpha-synuclein gene in patients with Parkinson’s disease.Mov Disord 16: 1115–1119, 2001.
Chan P, Jiang X, Forno LS, Di Monte DA, Tanner CM, Langston JW. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson’s disease.Neurology 50: 1136–1137, 1998.
Farrer M, Wavrant-De Vrieze F, Crook R, Boles L, Perez-Tur J, Hardy J et al. Low frequency of alpha-synuclein mutations in familial Parkinson’s disease.Ann Neurol 43: 394–397, 1998.
Vaughan JR, Farrer MJ, Wszolek ZK, Gasser T, Durr A, Agid Y et al. Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson’s disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson’s Disease (GSPD).Hum Mol Genet 7: 751–753, 1998.
Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS et al. Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53—Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice.Proc Natl Acad Sci USA 99: 8968–8973, 2002.
Feany MB, Bender WW. A Drosophila model of Parkinson’s disease.Nature 404: 394–398, 2000.
Gasser T, Müller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V et al. A susceptibility locus for Parkinson’s disease maps to chromosome 2p13.Nat Genet 18: 262–265, 1998.
Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11,2-q13,1.Ann Neurol 51: 296–301, 2002.
Yamamura Y, Sobue I, Ando K, Iida M, Yanagi T, Kondo C. Paralysis agitans of early-onset with marked diurnal fluctuation of symptoms.Neurology 23: 239–244, 1973.
Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile Parkinsonism.Neurology 47: 160–166, 1996.
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.Nature 392: 605–608, 1998.
Lücking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. French Parkinson’s Disease Genetics Study Group.N Engl J Med 342: 1560–1567, 2000.
Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease.Neurology 60: 796–801, 2003.
Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP et al. Parkin mutations and susceptibility alleles in late-onset Parkinson’s disease.Ann Neurol 53: 624–629, 2003.
Tan LC, Tanner CM, Chen R, Chan P, Farrer M, Hardy J et al. Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation.Mov Disord 18: 758–763, 2003.
Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A et al. Linkage stratification and mutation analysis at the parkin locus identifies mutation positive, Parkinson disease families.J Med Genet 39: 489–492, 2002.
Kann M, Jacobs H, Mohrmann K, Schumacher K, Hedrich K, Garrels J et al. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism.Ann Neurol 51: 621–625, 2002.
West A, Periquet M, Lincoln S, Lücking CB, Nicholl D, Bonifati V et al. Complex relationship between parkin mutations and Parkinson disease.Am J Med Genet 114: 584–591, 2002.
Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H et al. Evaluation of 50 probands with early-onset Parkinson’s disease for parkin mutations.Neurology 58: 1239–1246, 2002.
Lücking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. French Parkinson’s Disease Genetics Study Group.N Engl J Med 342: 1560–1567, 2000.
Abbas N, Lücking CB, Ricard S, Durr A, Bonifati V, De Michele G et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson’s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson’s Disease.Hum Mol Genet 8: 567–574, 1999.
Lücking CB, Abbas N, Durr A, Bonifati V, Bonnet AM, de Broucker T et al. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson’s Disease and the French Parkinson’s Disease Genetics Study Group.Lancet 352: 1355–1356, 1998.
Klein C, Pramstaller PP, Kis B, Page CC, Kann M, Leung J et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.Ann Neurol 48: 65–71, 2000.
Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D et al. Lewy bodies and parkinsonism in families with parkin mutations.Ann Neurol 50: 293–300, 2001.
Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on chromosome 1p35-p36.Am J Hum Genet 68: 895–900, 2001.
Valente EM, Brancati F, Ferraris A, Graham EA, Davis MB, Breteler MM et al. PARK6-linked parkinsonism occurs in several European families.Ann Neurol 51: 14–18, 2002.
van Duijn CM, Dekker MCJ, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ et al. PARK7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.Am J Hum Genet 69: 629–634, 2001.
Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.Science 299: 256–259, 2003.
Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras.Biochem Biophys Res Commun 231: 509–513, 1997.
Wagenfeld A, Gromoll J, Cooper TG. Molecular cloning and expression of rat contraception associated protein 1 (CAP1), a protein putatively involved in fertilization.Biochem Biophys Res Commun 251: 545–549, 1998.
Okada M, Matsumoto K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H. DJ-1, a target protein for an endocrine disrupter, participates in the fertilization in mice.Biol Pharm Bull 25: 853–856, 2002.
Mitsumoto A, Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin.Free Radic Res 35: 885–893, 2001.
Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E et al. The ubiquitin pathway in Parkinson’s disease.Nature 395: 451–452, 1998.
Wintermeyer P, Kruger R, Kuhn W, Muller T, Woitalla D, Berg D et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson’s disease patients.NeuroReport 11: 2079–2082, 2000.
Pickart CM. Ubiquitin in chains.Trends Biochem Sci 25: 544–548, 2000.
Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.Nat Med 7: 1144–1150, 2001.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations.Am J Hum Genet 71: 124–135, 2002.
Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K et al. Complete genomic screen in Parkinson disease: evidence for multiple genes.JAMA 286: 2239–2244, 2001.
Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J et al. A susceptibility gene for late-onset idiopathic Parkinson’s disease.Ann Neurol 52: 549–555, 2002.
Marx FP, Holzmann C, Strauss KM, Li L, Eberhardt O, Gerhardt E et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson’s disease.Hum Mol Genet 12: 1223–1231, 2003.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C et al. Significant linkage of Parkinson disease to chromosome 2q36-37.Am J Hum Genet 72: 1053–1057, 2003.
DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.Am J Hum Genet 70: 1089–1095, 2002.
Pankratz N, Uniacke SK, Halter C, Rudolph A, Shults C, Conneallyu PM et al. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci.Neurology (in press)
Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA et al. Age at onset in two common neurodegenerative diseases is genetically controlled.Am J Hum Genet 70: 985–993, 2002.
Mellick GD, Buchanan DD, McCann SJ, James KM, Johnson AG, Davis DR et al. Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson’s disease.Mov Disord 14: 219–224, 1999.
Grevle L, Guzey C, Hadidi H, Brennersted R, Idle JR, Aasly J. Allelic association between the DRD2 TaqI A polymorphism and Parkinson’s disease.Mov Disord 15: 1070–1074, 2000.
Nicholl DJ, Bennett P, Hiller L, Bonifati V, Vanacore N, Fabbrini G et al. A study of five candidate genes in Parkinson’s disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism.Neurology 53: 1415–1421, 1999.
Spielman RS, Ewens WJ. The TDT and other family-based tests for linkage disequilibrium and association.Am J Hum Genet 59: 983–989, 1996.
Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T et al. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson’s disease.Neurology 58: 881–884, 2002.
Zheng K, Heydari B, Simon DK. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease.Arch Neurol 60: 722–725, 2003.
Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG et al. Mutations in NR4A2 associated with familial Parkinson disease.Nat Genet 33: 85–89, 2003.
van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease.Am J Hum Genet 72: 804–811, 2003.
Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.Nat Genet 25: 302–305, 2000.
Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease.Science 293: 263–269, 2001.
Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1.Proc Natl Acad Sci USA 97: 13354–13359, 2000.
Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin.Cell 105: 891–902, 2001.
Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins.J Cell Biol 143: 1883–1898, 1998.
Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, Ciechanover A et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-in-duced pathology in SCA1 mice.Neuron 24: 879–892, 1999.
Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C et al. L166P mutant DJ-1, causative for recessive Parkinson’s disease, is degraded through the ubiquitin-proteasome system.J Biol Chem 278: 36588–36595, 2003.
Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure.J Biol Chem 276: 44284–442896, 2001.
Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D. Alpha-synuclein implicated in Parkinson’s disease catalyses the formation of hydrogen peroxide in vitro.Free Radic Biol Med 30: 1163–11670, 2001.
Ischiropoulos H. Oxidative modifications of alpha-synuclein.Ann NY Acad Sci 991: 93–100, 2003.
Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.Nat Med 8: 600–606, 2002.
Burke WJ. Recent advances in the genetics and pathogenesis of Parkinson’s disease.Neurology 59: 1118, 2002.
Wersinger C, Prou D, Vernier P, Sidhu A. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress.FASEB J 17(14): 2151–3, 2003.
Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.FASEB J 15: 916–926, 2001.
McCusker EA. The specialist neurologist and the “new genetics”.Med J Aust 179: 167–169, 2003.
Greely HT. Special issues in genetic testing for Alzheimer disease.Genet Test 3: 115–119, 1999.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pankratz, N., Foroud, T. Genetics of Parkinson disease. Neurotherapeutics 1, 235–242 (2004). https://doi.org/10.1602/neurorx.1.2.235
Issue Date:
DOI: https://doi.org/10.1602/neurorx.1.2.235